Q1 EPS Forecast for Sage Therapeutics Boosted by Analyst
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...
Yahoo Finance9d
Q4 2024 SAGE Therapeutics Inc Earnings Call
Paul Matteis; Analyst; Stifel, Nicolaus & Company, Inc. Good afternoon. Welcome to Sage Therapeutics' fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions) This ...
Sage Therapeutics’ (SAGE) “Hold” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. Other equities ...
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
The Harvard Crimson9d
Cambridge Biopharma Firm Sage Therapeutics Sues Partner Biogen After Buyout Offer
Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
SAGE Therapeutics (SAGE) Gets a Buy from Scotiabank
Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.